Please enable JS

News

LATEST PRESS RELEASES & NEWS ITEMS


DIVIDE & CONQUER EMERGES FROM STEALTH AS NEW PAPER BY CO-FOUNDER IS PUBLISHED IN NATURE

Cambridge, UK – 18 September 2019 : Divide & Conquer, a biotechnology company formed in 2018 with a £10 million (approximately $13.1 million) Series A financing from Medicxi, has left stealth mode to mark the publication of another paper in Nature co-authored by one of its founders, Prof. Frank Winkler of Heidelberg University...
MORE

CHEMICAL & ENGINEERING NEWS -BIOTECH START-UP DIVIDE & CONQUER LAUNCHES TO DISRUPT CANCER CELL COMMUNICATION

Ryan Cross : In November 2014, biologist Miroslav Radman was thinking a lot about social networks, but not the kind we obsess over on our computers and phones. Instead, he was interested in the social networks of cells...
MORE

BIOCENTURY - DIVIDE & CONQUER: SHORT-CIRCUITING TUMOR LINES OF COMMUNICATION

Stephen Hansen : Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy....
MORE

LABIOTECH.EU - UK CANCER BIOTECH RAISES €11M SERIES A TO BREAK UP BRAIN TUMORS

Jonathan Smith : With this Series A round, funded by the UK VC firm Medicxi, Divide and Conquer has exited stealth mode a year after its foundation. The company will use the money to take its lead candidate drug for the treatment of glioblastoma to its first study in humans, expected to start by the end of 2020...
MORE

ENDPOINTS NEWS : 'DISCONNECT THE BASTARDS'— ONE BIOTECH'S PLAN TO BREAK CANCER CELLS' UNIFIED DEFENSES

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects..
MORE

FIERCEBIOTECH : MEDICXI FOUNDS BIOTECH TO DIVIDE & CONQUER TOUGH SOLID TUMORS

Moncef Slaoui and his colleagues at Medicxi have taken the wraps off a new oncology startup, Divide & Conquer..
MORE

CELLULAR SOCIAL NETWORKS GIVE CANCER CELLS A CLOAK OF INVINCIBILITY by DrugBaron

Ever since DrugBaron studied biochemistry at the end of the 1980s, one question about cancer has always perplexed him: why can we induce almost complete remission and yet the cancer can come back stronger and invariably kill the patient? ...
MORE